U.S. markets open in 1 hour 27 minutes
  • S&P Futures

    3,775.25
    -18.75 (-0.49%)
     
  • Dow Futures

    30,167.00
    -143.00 (-0.47%)
     
  • Nasdaq Futures

    11,576.75
    -47.00 (-0.40%)
     
  • Russell 2000 Futures

    1,757.10
    -10.90 (-0.62%)
     
  • Crude Oil

    87.35
    -0.41 (-0.47%)
     
  • Gold

    1,722.70
    +1.90 (+0.11%)
     
  • Silver

    20.63
    +0.09 (+0.42%)
     
  • EUR/USD

    0.9869
    -0.0016 (-0.16%)
     
  • 10-Yr Bond

    3.7590
    0.0000 (0.00%)
     
  • Vix

    29.19
    +0.12 (+0.41%)
     
  • GBP/USD

    1.1258
    -0.0064 (-0.56%)
     
  • USD/JPY

    144.6750
    +0.0650 (+0.04%)
     
  • BTC-USD

    20,236.58
    +202.77 (+1.01%)
     
  • CMC Crypto 200

    459.93
    +1.52 (+0.33%)
     
  • FTSE 100

    6,996.36
    -56.26 (-0.80%)
     
  • Nikkei 225

    27,311.30
    +190.80 (+0.70%)
     

Evotec, Alpine Expand Pact For Commercial Process Development Of Autoimmune Disease Candidate

·1 min read
  • Evotec SE's (NASDAQ: EVO) subsidiary, Just - Evotec Biologics Inc, has expanded a multi-year partnership with Alpine Immune Sciences Inc (NASDAQ: ALPN) for ALPN-303 for systemic lupus erythematosus and other B cell-mediated inflammatory and autoimmune diseases.

  • The contract is a continuation of their first-in-human program initiated in 2020, in which Just - Evotec Biologics delivered drug substance materials using their J.DESIGN continuous manufacturing platform for Alpine's ongoing Phase 1 study and anticipated Phase 2 studies of ALPN-303.

  • Related: Alpine Immune Sciences' Autoimmune Disease Candidate ALPN-303 Shows Promise in Preclinical Studies.

  • Under the expanded contract, Just - Evotec Biologics will leverage its data-driven technology platform to develop a commercial manufacturing process for ALPN-303.

  • Commercial process development activities will be performed at Just - Evotec Biologics' J.POD biomanufacturing facility in Redmond, Washington.

  • Price Action: EVO shares are down 12.7% at $12.33 during the premarket session on the last check Wednesday. ALPN stock closed at $8.49 on Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.